Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Issues Earnings Results

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) issued its quarterly earnings data on Monday. The company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.04, Zacks reports. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.88% and a return on equity of 8.90%.

Fresenius Medical Care AG & Co. KGaA Trading Down 1.3%

FMS traded down $0.34 during mid-day trading on Monday, reaching $25.32. The stock had a trading volume of 1,157,038 shares, compared to its average volume of 676,914. The firm’s fifty day simple moving average is $23.32 and its two-hundred day simple moving average is $22.94. The stock has a market capitalization of $13.60 billion, a P/E ratio of 13.33, a P/E/G ratio of 4.56 and a beta of 0.77. Fresenius Medical Care AG & Co. KGaA has a 52 week low of $20.02 and a 52 week high of $27.64. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.86 and a current ratio of 1.20.

Hedge Funds Weigh In On Fresenius Medical Care AG & Co. KGaA

Large investors have recently made changes to their positions in the company. Brooklyn Investment Group boosted its holdings in Fresenius Medical Care AG & Co. KGaA by 5.4% in the fourth quarter. Brooklyn Investment Group now owns 8,860 shares of the company’s stock valued at $212,000 after acquiring an additional 450 shares during the last quarter. Arax Advisory Partners raised its holdings in Fresenius Medical Care AG & Co. KGaA by 121.6% during the 4th quarter. Arax Advisory Partners now owns 1,613 shares of the company’s stock worth $38,000 after purchasing an additional 885 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in Fresenius Medical Care AG & Co. KGaA by 21.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 5,096 shares of the company’s stock worth $146,000 after purchasing an additional 896 shares during the last quarter. CIBC Private Wealth Group LLC lifted its position in Fresenius Medical Care AG & Co. KGaA by 398.2% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock valued at $36,000 after purchasing an additional 1,103 shares during the period. Finally, Cerity Partners LLC lifted its position in Fresenius Medical Care AG & Co. KGaA by 3.1% during the 2nd quarter. Cerity Partners LLC now owns 41,126 shares of the company’s stock valued at $1,175,000 after purchasing an additional 1,223 shares during the period. Institutional investors and hedge funds own 8.37% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on FMS shares. Sanford C. Bernstein assumed coverage on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Thursday, July 16th. They issued a “market perform” rating for the company. Zacks Research upgraded Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Morgan Stanley reaffirmed an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Wednesday, May 6th. Citigroup reaffirmed a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Friday, July 17th. Finally, Jefferies Financial Group raised Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “moderate sell” rating in a research note on Friday, May 8th. Six investment analysts have rated the stock with a Hold rating and five have given a Sell rating to the company. Based on data from MarketBeat, Fresenius Medical Care AG & Co. KGaA has a consensus rating of “Reduce” and a consensus price target of $23.95.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high?flux dialyzers and bloodlines.